Literature DB >> 27058970

Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial.

Daniel H Solomon1, Sara B Lee2, Agnes Zak2, Cassandra Corrigan2, Jenifer Agosti3, Asaf Bitton4, Leslie Harrold5, Elena Losina6, Bing Lu2, Ted Pincus7, Helga Radner8, Josef Smolen8, Jeffrey N Katz9, Liana Fraenkel10.   

Abstract

BACKGROUND/
PURPOSE: Treat-to-target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but various data sources suggest that its uptake in routine care in the US is suboptimal. Herein, we describe the design of a randomized controlled trial of a Learning Collaborative to facilitate implementation of TTT.
METHODS: We recruited 11 rheumatology sites from across the US and randomized them into the following two groups: one received the Learning Collaborative intervention in Phase 1 (month 1-9) and the second formed a wait-list control group to receive the intervention in Phase 2 (months 10-18). The Learning Collaborative intervention was designed using the Model for Improvement, consisting of a Change Package with corresponding principles and action phases. Phase 1 intervention practices had nine learning sessions, collaborated using a web-based tool, and shared results of plan-do-study-act cycles and monthly improvement metrics collected at each practice. The wait-list control group sites had no intervention during Phase 1. The primary trial outcome is the implementation of TTT as measured by chart review, comparing the differences from baseline to end of Phase 1, between intervention and control sites.
RESULTS: All intervention sites remained engaged in the Learning Collaborative throughout Phase 1, with a total of 38 providers participating. The primary trial outcome measures are currently being collected by the study team through medical record review.
CONCLUSIONS: If the Learning Collaborative is an effective means for improving implementation of TTT, this strategy could serve as a way of implementing disseminating TTT more widely.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Learning collaborative; Quality improvement; Randomized controlled trial; Rheumatoid arthritis; Treat to target

Mesh:

Year:  2016        PMID: 27058970      PMCID: PMC4969092          DOI: 10.1016/j.semarthrit.2016.02.009

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  27 in total

Review 1.  The importance of the normality assumption in large public health data sets.

Authors:  Thomas Lumley; Paula Diehr; Scott Emerson; Lu Chen
Journal:  Annu Rev Public Health       Date:  2001-10-25       Impact factor: 21.981

2.  Using a virtual breakthrough series collaborative to improve access in primary care.

Authors:  Barbara Boushon; Lloyd Provost; Janice Gagnon; Penny Carver
Journal:  Jt Comm J Qual Patient Saf       Date:  2006-10

Review 3.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

4.  Measuring the effectiveness of a collaborative for quality improvement in pediatric asthma care: does implementing the chronic care model improve processes and outcomes of care?

Authors:  Rita Mangione-Smith; Matthias Schonlau; Kitty S Chan; Joan Keesey; Mayde Rosen; Thomas A Louis; Emmett Keeler
Journal:  Ambul Pediatr       Date:  2005 Mar-Apr

5.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

6.  Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.

Authors:  L H D van Tuyl; W F Lems; A E Voskuyl; P J S M Kerstens; P Garnero; B A C Dijkmans; M Boers
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

7.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

Review 8.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

Review 9.  Systematic review of the application of the plan-do-study-act method to improve quality in healthcare.

Authors:  Michael J Taylor; Chris McNicholas; Chris Nicolay; Ara Darzi; Derek Bell; Julie E Reed
Journal:  BMJ Qual Saf       Date:  2013-09-11       Impact factor: 7.035

10.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

View more
  9 in total

1.  Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial.

Authors:  Daniel H Solomon; Bing Lu; Zhi Yu; Cassandra Corrigan; Leslie R Harrold; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz; Elena Losina
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-10       Impact factor: 4.794

2.  Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study.

Authors:  Julie Gandrup; Jing Li; Zara Izadi; Milena Gianfrancesco; Torkell Ellingsen; Jinoos Yazdany; Gabriela Schmajuk
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-01-09       Impact factor: 4.794

Review 3.  Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches.

Authors:  Ann M Chodara; Aimée Wattiaux; Christie M Bartels
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

4.  Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial.

Authors:  Daniel H Solomon; Elena Losina; Bing Lu; Agnes Zak; Cassandra Corrigan; Sara B Lee; Jenifer Agosti; Asaf Bitton; Leslie R Harrold; Theodore Pincus; Helga Radner; Zhi Yu; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz
Journal:  Arthritis Rheumatol       Date:  2017-05-31       Impact factor: 10.995

5.  RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.

Authors:  Gabriela Schmajuk; Jing Li; Michael Evans; Christine Anastasiou; Zara Izadi; Julia L Kay; Nevin Hammam; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2020-03-19       Impact factor: 5.532

6.  Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.

Authors:  Daniel H Solomon; Zhi Yu; Jeffrey N Katz; Asaf Bitton; Cassandra Corrigan; Liana Fraenkel; Leslie R Harrold; Josef S Smolen; Elena Losina; Bing Lu
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-19       Impact factor: 4.794

Review 7.  Treat-to-target in PsA: methods and necessity.

Authors:  Emma Dures; Sasha Shepperd; Sandeep Mukherjee; Jo Robson; Ivo Vlaev; Nicola Walsh; Laura C Coates
Journal:  RMD Open       Date:  2020-02

8.  Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle Study.

Authors:  Maria I Danila; Lang Chen; Eric M Ruderman; Justin K Owensby; Ronan O'Beirne; Joshua A Melnick; Leslie R Harrold; David Curtis; W Benjamin Nowell; Jeffrey R Curtis
Journal:  ACR Open Rheumatol       Date:  2021-12-27

9.  Implementing a Treat-to-Target Approach for Rheumatoid Arthritis During the COVID-19 Pandemic: Results of a Virtual Learning Collaborative Program.

Authors:  Daniel H Solomon; Theodore Pincus; Nancy A Shadick; Jacklyn Stratton; Jack Ellrodt; Leah Santacroce; Jeffrey N Katz; Josef S Smolen
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-02-04       Impact factor: 5.178

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.